You just read:

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy

News provided by

Shire plc

Mar 06, 2017, 13:55 ET